The Brucellosis Market is
expected to reach USD 0.63 Billion by 2032 at 8.9% CAGR during the forecast
period 2023-2032.
The Brucellosis market is witnessing steady growth due to increasing
awareness, rising incidence rates, and advancements in diagnostic and treatment
options. Brucellosis, caused by bacteria of the genus Brucella, affects both
animals and humans, primarily transmitted through direct contact with infected
animals or consumption of contaminated animal products.
The market is driven by
government initiatives to control and eradicate the disease, especially in
regions with high prevalence rates. Diagnostic methods such as serology, PCR,
and culture-based tests are gaining traction, enabling early detection and treatment.
Additionally, the development of novel vaccines and antibiotics contributes to
market expansion, catering to the growing demand for effective prevention and
management strategies.
Brucellosis, caused by the
bacteria Brucella, remains a significant concern globally, affecting both
animals and humans. The Brucellosis market revolves around prevention,
diagnosis, and treatment strategies to combat this infectious disease. Brucella disease poses serious health risks, including fever,
joint pain, fatigue, and potentially life-threatening complications if left
untreated. Hence, efficient Brucellosis diagnosis methods are pivotal for
timely intervention.
In the Brucellosis market,
advanced diagnostic techniques play a crucial role in identifying the infection
accurately. Diagnostic methods include serological tests, bacterial culture,
PCR assays, and imaging studies to detect Brucella species and assess the
extent of infection. These diagnostic tools enable healthcare professionals to
initiate appropriate treatment promptly, mitigating the spread of the disease.
Furthermore, the Brucellosis
market emphasizes the development of innovative diagnostic technologies to
enhance sensitivity, specificity, and rapidity in detecting Brucella pathogens.
Point-of-care tests and molecular diagnostics are gaining traction for their
effectiveness in resource-limited settings.
Investments in research and
development aim to expand the Brucellosis market by introducing novel
therapeutics and vaccines. Additionally, public health initiatives and
awareness campaigns are vital for preventing Brucellosis transmission and
fostering early detection practices.
Regional
Analysis:
Global
brucellosis consists of regions namely the Americas, Europe, Asia Pacific, and
the Middle East.
The
European market dominated the global brucellosis market owing to the high
prevalence rate of this disease in the Eastern European regions. America holds
the second largest share for the global brucellosis market owing to the
increasing research and development in biotechnology and pharmaceutical
companies especially for study of genomics and diagnosis testing which play
significant role in driving the global brucellosis market.
Asia
Pacific is expected to be the fastest growing region and is anticipated to
compete with the American market. during the forecasted period 2017 to
2023. Brucellosis remains an uncontrolled problem in regions of high
endemicity such as the Mediterranean, the Middle East, Africa, Latin America,
and parts of Asia. The presence of brucellosis in India was first established
early in the previous century and since then has been reported from almost all
states. Furthermore, brucellosis is the most common bacterial laboratory
acquired infection worldwide.
Segmentation:
The
brucellosis is segmented based on species, diagnosis, treatment and end-users.
On the
basis of species, the market is segmented into Brucella suis, Brucella
abortus, Brucella melitensis, Brucella Canis and others.
On the
basis of diagnosis, market is segmented into serological tests, molecular
techniques, bone marrow biopsy, X-rays, computerized tomography (CT), magnetic
resonance imaging (MRI), cerebrospinal fluid culture, echocardiography and
others. The serological tests is segmented into serum agglutination test, rose
bengal test, lateral flow assay, compliment fixation test, coombs test, enzyme
linked immuno sorbent assaym, and immunocapture-agglutination test
(brucellacapt). The molecular techniques is segmented into Polymerase Chain
Reaction (PCR), Loop- mediated isothermal amplification assay, Multiple Locus
VNTR Analysis (MLVA) typing. The Polymerase Chain Reaction (PCR) is further
classified into standard PCR, real time PCR, nested PCR, PCR based assays.
On the
basis of treatment market is segmented into antibiotics, vaccines, and others.
On the
basis of end-user, the market is segmented into hospitals & diagnostic
centers, academic institutes, pharmaceutical & biotechnology companies and
others.
Key
Players:
The global brucellosiss companies are Hester Biosciences Limited, ATA FEN Inc.,
Biogénesis-Bagó S.A., Biopharma, Biovet, Calier & Biologicos Laverlam,
Merck Animal Health (MSD Animal Health), Colorado Serum Company, Indian
Immunologicals Limited, Dollvet, Veterinary Technologies Corporation, China
Animal Husbandry Co., Ltd. (CAHIC), LABIOFAM, BCG Vaccine Laboratory, and
others.
Related
Reports:
Flash
Chromatography Market
Real-Time
PCR (qPCR) Market
2D
Chromatography Market
For More Information, Please
Visit @ Market
Research Future
Comments
Post a Comment